Cargando…

Dual Inhibition of Phosphodiesterase and Ca(++) Channels Explains the Medicinal Use of Balanites aegyptiaca (L.) in Hyperactive Gut Disorders

The present study attempted to evaluate and rationalize the medicinal use of the methanolic extract of the fruits of Balanites aegyptiaca (B. aegyptiaca) in the treatment of hyperactive gut disorders. The in vivo, castor oil-induced diarrhea model in mice was followed to test its antidiarrheal effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehman, Najeeb Ur, Ansari, Mohd Nazam, Ahmad, Wasim, Ahamad, Syed Rizwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105777/
https://www.ncbi.nlm.nih.gov/pubmed/35567184
http://dx.doi.org/10.3390/plants11091183
_version_ 1784708122512719872
author Rehman, Najeeb Ur
Ansari, Mohd Nazam
Ahmad, Wasim
Ahamad, Syed Rizwan
author_facet Rehman, Najeeb Ur
Ansari, Mohd Nazam
Ahmad, Wasim
Ahamad, Syed Rizwan
author_sort Rehman, Najeeb Ur
collection PubMed
description The present study attempted to evaluate and rationalize the medicinal use of the methanolic extract of the fruits of Balanites aegyptiaca (B. aegyptiaca) in the treatment of hyperactive gut disorders. The in vivo, castor oil-induced diarrhea model in mice was followed to test its antidiarrheal effect. To test the antispasmodic effect and to explore its pharmacodynamic details, isolated small intestines (ileum) obtained from rats were selected to provide physiological conditions for the ex vivo assays. In the in vivo assays, the orally administered extract of B. aegyptiaca protected mice from diarrheal drops with resultant percent inhibitions of 40% and 80% at the respective doses of 200 mg/kg and 400 mg/kg, while the highest protection (100%) was observed with a positive control drug, loperamide, at 10 mg/kg. In the ileum, B. aegyptiaca produced an antispasmodic effect in a concentration-dependent manner by inhibiting the carbachol (CCh; 1 µM) and high K(+) (80 mM)-evoked spasms with resultant EC(50) values of 1.44 mg/mL (1.08–1.78) and 1.27 mg/mL (0.98–1.66), respectively. Papaverine, a known phosphodiesterase enzyme (PDE) inhibitor and blocker of Ca(++) channels (CCB), also inhibited both CCh and high K(+) induced contractions at comparable EC(50) values of 8.72 µM (7.92–9.24) and 8.14 µM (7.62–8.84), respectively. Contrary to the extract and papaverine, verapamil showed distinctly higher potency in regard to inhibiting high K(+), compared to CCh-evoked spasms that had EC(50) values of 0.16 µM (0.13–0.261) and 2.54 µM (2.28–2.92), respectively. The inhibitory effects of B. aegyptiaca on PDE were further confirmed when the pre-incubated extract shifted the isoprenaline-mediated relaxation curves (CRCs) towards the left, similar to papaverine, whereas the CCB-like effect was confirmed when the pre-incubated tissues with B. aegyptiaca caused deflection in the Ca(++) CRCs towards the right, constructed in Ca(++) free medium with suppression of the maximum response. Thus, this study provides detailed, mechanistic support for the medicinal use of B. aegyptiaca in the treatment of hyperactive gut disorders.
format Online
Article
Text
id pubmed-9105777
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91057772022-05-14 Dual Inhibition of Phosphodiesterase and Ca(++) Channels Explains the Medicinal Use of Balanites aegyptiaca (L.) in Hyperactive Gut Disorders Rehman, Najeeb Ur Ansari, Mohd Nazam Ahmad, Wasim Ahamad, Syed Rizwan Plants (Basel) Article The present study attempted to evaluate and rationalize the medicinal use of the methanolic extract of the fruits of Balanites aegyptiaca (B. aegyptiaca) in the treatment of hyperactive gut disorders. The in vivo, castor oil-induced diarrhea model in mice was followed to test its antidiarrheal effect. To test the antispasmodic effect and to explore its pharmacodynamic details, isolated small intestines (ileum) obtained from rats were selected to provide physiological conditions for the ex vivo assays. In the in vivo assays, the orally administered extract of B. aegyptiaca protected mice from diarrheal drops with resultant percent inhibitions of 40% and 80% at the respective doses of 200 mg/kg and 400 mg/kg, while the highest protection (100%) was observed with a positive control drug, loperamide, at 10 mg/kg. In the ileum, B. aegyptiaca produced an antispasmodic effect in a concentration-dependent manner by inhibiting the carbachol (CCh; 1 µM) and high K(+) (80 mM)-evoked spasms with resultant EC(50) values of 1.44 mg/mL (1.08–1.78) and 1.27 mg/mL (0.98–1.66), respectively. Papaverine, a known phosphodiesterase enzyme (PDE) inhibitor and blocker of Ca(++) channels (CCB), also inhibited both CCh and high K(+) induced contractions at comparable EC(50) values of 8.72 µM (7.92–9.24) and 8.14 µM (7.62–8.84), respectively. Contrary to the extract and papaverine, verapamil showed distinctly higher potency in regard to inhibiting high K(+), compared to CCh-evoked spasms that had EC(50) values of 0.16 µM (0.13–0.261) and 2.54 µM (2.28–2.92), respectively. The inhibitory effects of B. aegyptiaca on PDE were further confirmed when the pre-incubated extract shifted the isoprenaline-mediated relaxation curves (CRCs) towards the left, similar to papaverine, whereas the CCB-like effect was confirmed when the pre-incubated tissues with B. aegyptiaca caused deflection in the Ca(++) CRCs towards the right, constructed in Ca(++) free medium with suppression of the maximum response. Thus, this study provides detailed, mechanistic support for the medicinal use of B. aegyptiaca in the treatment of hyperactive gut disorders. MDPI 2022-04-27 /pmc/articles/PMC9105777/ /pubmed/35567184 http://dx.doi.org/10.3390/plants11091183 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rehman, Najeeb Ur
Ansari, Mohd Nazam
Ahmad, Wasim
Ahamad, Syed Rizwan
Dual Inhibition of Phosphodiesterase and Ca(++) Channels Explains the Medicinal Use of Balanites aegyptiaca (L.) in Hyperactive Gut Disorders
title Dual Inhibition of Phosphodiesterase and Ca(++) Channels Explains the Medicinal Use of Balanites aegyptiaca (L.) in Hyperactive Gut Disorders
title_full Dual Inhibition of Phosphodiesterase and Ca(++) Channels Explains the Medicinal Use of Balanites aegyptiaca (L.) in Hyperactive Gut Disorders
title_fullStr Dual Inhibition of Phosphodiesterase and Ca(++) Channels Explains the Medicinal Use of Balanites aegyptiaca (L.) in Hyperactive Gut Disorders
title_full_unstemmed Dual Inhibition of Phosphodiesterase and Ca(++) Channels Explains the Medicinal Use of Balanites aegyptiaca (L.) in Hyperactive Gut Disorders
title_short Dual Inhibition of Phosphodiesterase and Ca(++) Channels Explains the Medicinal Use of Balanites aegyptiaca (L.) in Hyperactive Gut Disorders
title_sort dual inhibition of phosphodiesterase and ca(++) channels explains the medicinal use of balanites aegyptiaca (l.) in hyperactive gut disorders
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105777/
https://www.ncbi.nlm.nih.gov/pubmed/35567184
http://dx.doi.org/10.3390/plants11091183
work_keys_str_mv AT rehmannajeebur dualinhibitionofphosphodiesteraseandcachannelsexplainsthemedicinaluseofbalanitesaegyptiacalinhyperactivegutdisorders
AT ansarimohdnazam dualinhibitionofphosphodiesteraseandcachannelsexplainsthemedicinaluseofbalanitesaegyptiacalinhyperactivegutdisorders
AT ahmadwasim dualinhibitionofphosphodiesteraseandcachannelsexplainsthemedicinaluseofbalanitesaegyptiacalinhyperactivegutdisorders
AT ahamadsyedrizwan dualinhibitionofphosphodiesteraseandcachannelsexplainsthemedicinaluseofbalanitesaegyptiacalinhyperactivegutdisorders